Infectious and Tropical Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Department of Molecular Medicine, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.
J Cell Physiol. 2019 Aug;234(8):12341-12352. doi: 10.1002/jcp.28038. Epub 2019 Jan 4.
microRNAs (miRNAs), as a group of noncoding RNAs, posttranscriptionally control gene expression by binding to 3'-untranslated region (3'-UTR). Ras-associated binding (Rab) proteins function as molecular switches for regulating vesicular transport, which mainly have oncogenic roles in cancer development and preventing the efficacy of chemotherapies. Increased evidence supported that miRNAs/Rabs interaction have been determined as potential therapeutics for cancer therapy. Nevertheless, instability and cross-targeting of miRNAs are main limitations of using miRNA-based therapeutic. The mutual interplay between Rabs and miRNAs has been poorly understood. In the present review, we focused on the essence and activity of these molecules in cancer pathogenesis. Also, numerous hindrances and potential methods in the expansion of miRNA as an anticancer therapeutics are mentioned.
微小 RNA（miRNAs）作为一组非编码 RNA，通过与 3'非翻译区（3'-UTR）结合来转录后控制基因表达。Ras 相关结合（Rab）蛋白作为调节囊泡运输的分子开关，在癌症发展和防止化疗疗效方面主要具有致癌作用。越来越多的证据表明，miRNAs/Rabs 相互作用已被确定为癌症治疗的潜在治疗方法。然而，miRNA 的不稳定性和交叉靶向是 miRNA 治疗应用的主要限制。Rab 蛋白和 miRNAs 之间的相互作用还了解甚少。在本综述中，我们重点关注这些分子在癌症发病机制中的本质和活性。此外，还提到了 miRNA 作为抗癌治疗剂扩展的许多障碍和潜在方法。
